<< Вернуться к списку статей журнала

Том 13 №1 2011 год - Нефрология и диализ

Национальные рекомендации по МКН-ХБП: преемственность, современное состояние и перспективы (вместо предисловия)

Земченков А.Ю. Герасимчук Р.П.

Аннотация: Вышедшие в свет в августе 2009 года рекомендации KDIGO по минеральным и костным нарушениям при хронической болезни почек построены на строгих принципах доказательной медицины, но и при отсутствии строгих доказательств могут использоваться как фундаментальная база для принятия решений у конкретных пациентов. Рассмотрение работ 2009–2010 годов, не вошедших в обоснования рекомендаций, или более ранних работ, не прошедших строгий отбор, а также наблюдательных исследований, поможет найти наиболее сбалансированные и целесообразные решения и избегнуть опасных крайностей в условиях, когда четкие рекомендации отсутствуют. Анализ представленных в настоящем обзоре работ, а также собственный клинический опыт позволили рабочей группе Российского Диализного Общества предложить адаптированный для российских условий вариант рекомендаций по МКН-ХБП. Мы надеемся на то, что их положения, регулярно обновляемые на специально созданном сайте www.ckd-mbd.ru, будут полезны практическим врачам.

Для цитирования: Земченков А.Ю., Герасимчук Р.П. Национальные рекомендации по МКН-ХБП: преемственность, современное состояние и перспективы (вместо предисловия). Нефрология и диализ. 2011. 13(1):020-030. doi:

Весь текст

Список литературы:

1. Герасимчук Р.П., Земченков А.Ю., Кондаков С.Б., Медведева Е. Малоинвазивный метод коррекции вторичного гиперпаратиреоза при хронической болезни почек // Врач. 2009. № 11. С. 13–19.
2. Ермоленко В.М., Родионова С.С., Павлова Е.А. и др. Спектр и лечение ренальной остеодистрофии у больных на постоянном амбулаторном перитонеальном диализе (собственные данные и обзор литературы) // Нефрология и диализ. 2004. Т. 6. № 2. С. 164–169.
3. Земченков А.Ю., Герасимчук Р.П. Сосудистая кальцификация и активаторы рецепторов витамина D. Обзор // Нефрология и диализ. 2009. Т. 11. № 4. С. 276–292.
4. Земченков А.Ю., Конакова И.Н. Классификация хронической болезни почек: не настало ли время для ее пересмотра // Врач. 2009. № 7. С. 2–7.
5. Земченков А.Ю., Томилина Н.А. K/DOQI обращается к истокам хронической почечной недостаточности // Нефрология и диализ. 2004. Т. 6. № 3. С. 204–220.
6. Клинические практические рекомендации K/DOQI (2003) по метаболизму кости и патологии скелета при хронических заболеваниях почек. Перевод с английского С.В. Лашутина // Нефрология и диализ. 2009. Приложение. С. 1–202.
7. Смирнов А.В., Есаян А.М., Каюков И.Г. Хроническая болезнь почек: на пути к единству представлений // Нефрология. 2002. Т. 6. № 4. С. 11–17.
8. Arenas M.D., Rebollo P., Malek T. et al. A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice // J Nephrol. 2010. Vol. 23. № 6. P. 3683–3692.
9. Barreto D.V., Barreto F.C., Carvalho A.B. et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study // Am J Kidney Dis. 2008. Vol. 52. № 6. P. 1139–1350.
10. Blayney M.J., Tentori F. Trends and consequences of mineral bone disorder in haemodialysis patients: Lessons from the dialysis outcomes and practice patterns study (DOPPS) // Journal of Renal Care. 2009. Vol. 35. S1. P. 7–13.
11. Block G.A., Spiegel D.M., Ehrlich J. et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis // Kidney Int. 2005. Vol. 68. № 4. P. 1815–1824.
12. Block G.A., Zeig S., Sugihara J. et al. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism // Nephrol Dial Transplant. 2008. Vol. 23. № 7. P. 2311–2318.
13. Block G.A., Zaun D., Smits G. et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients // Kidney Int. 2010. Vol. 78. № 6. P. 578–589.
14. Campbell N., Pepper R.J., Yaqoob M.M. et al. The Use of Aluminium Containing Phosphate Binders in Haemodialysis Patients. ASN Renal week. 2009. Abstract PUB494.
15. Covic A., Fernandez-Martin J.L., Floege J. et al. Treatment of Secondary Hyperparathyroidism and K-DOQI Guidelines Achievement. COSMOS, a European Observational Study. Abstract F-PO1795 // J Am Soc Nephrol. 2008. Vol. 19. P. 507A.
16. Eknoyan G. Chronic kidney disease definition and classification: no need for a rush to judgment // Kidney Int. 2009. Vol. 75. № 10. P. 1015.
17. Fishbane S., Shapiro W.B., Corry D.B. et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results // Clin J Am Soc Nephrol. 2008. Vol. 3. № 6. P. 1718–1725.
18. Floege J., Wheeler D., Ireland E. et al. Serum PTH and Mortality Risk in a Large Cohort of European Hemodialysis (HD) Patients: 2-Year ARO Results. Abstract F-PO1746 // J Am Soc Nephrol. 2008. Vol. 19. P. 502A.
19. Foley R.N., Parfrey P.S., Harrnett J.D. et al. Hypocalcemia, Morbidity, and Mortality in End-Stage Renal Disease // Am J Nephrol. 1996. Vol. 16. P. 386–393.
20. Foley R.N., Li S., Liu J. et al. The Fall and Rise of Parathyroidectomy in U.S. Hemodialysis Patients, 1992 to 2002 // J Am Soc Nephrol. Vol. 16. № 1. P. 210–218.
21. de Francisco A.L.M., Leidig M., Covic A.C. et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability // Nephrol Dial Transplant. 2010. Vol. 25. P. 3707–3717.
22. Fukagawa M., Yumita S., Akizawa T. et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients // Nephrol Dial Transplant. 2008. Vol. 23. № 1. P. 328–335.
23. Goldsmith D., Covic A., Fouque D. et al. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement // NDT Advance Access published September 9, 2010, doi: 10.1093/ndt/gfq513
24. Hirai T., Nakashima A., Takasugi N. et al. Response of secondary hyperparathyroidism to cinacalcet depends on parathyroid size // Nephron Clin Pract. 2010. Vol. 114. № 3. P. 187–193.
25. http://clinicaltrials.gov/ct2/results?term = NCT00977080: Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
26. http://clinicaltrials.gov/ct2/show/study/NCT00497146?term = PRIMO&rank = 1
27. http://www.dopps.org/annualreport/html/pb_aub_c_TAB2009.htm
28. Huang C., Cheng K., Lin P. et al. Mortality Risk for Chinese Hemodialysis Patients with Disordered Bone Mineral Metabolism // ASN Renal week. 2009. Abstract F-PO1854.
29. Ichii M., Ishimurab E., Okuno S. et al. Decreases in Parathyroid Gland Volume after Cinacalcet Treatment in Hemodialysis Patients with Secondary Hyperparathyroidism // Nephron Clin Pract. 2010. Vol. 115. P. 195–202.
30. Jadoul M., Baños A., Zani V.J. et al. The effects of discontinuing cinacalcet at the time of kidney transplantation // NDT Plus. 2010. Vol. 3. № 1. P. 37–41.
31. Kalantar-Zadeh K., Gutekunst L., Mehrotra R. et al. Understanding Sources of Dietary Phosphorus in the Treatment of Patients with Chronic Kidney Disease // Clin J Am Soc Nephrol. 2010. Vol. 5. P. 519–530.
32. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) // Kidney Int. Suppl. 2009. Vol. 113. P. 1–130.
33. Kimata N., Akiba T., Pisoni R.L. et al. Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS) // Nephrol Dial Transplant. 2005. Vol. 20. P. 927–935.
34. Komaba H., Moriwaki K., Kamae I. et al. Towards cost-effective strategies for treatment of chronic kidney disease-mineral and bone disorder in Japan // Ther Apher Dial. 2009. Suppl. 1. P. 28–35.
35. Kovesdy C.P., Kuchmak O., Lu J.L. et al. Outcomes Associated With Phosphorus Binders in Men With Non–Dialysis-Dependent CKD // Am J Kidney Dis. Vol. 56. № 5. P. 842–851.
36. Levey A., Atkins R., Coresh J. et al. Chronic kidney disease as a global public health problem: approaches and initiatives – a position statement from Kidney Disease: Improving Global Outcomes // Kidney Int. 2007. Vol. 72. P. 247–259.
37. Levey A., Eckard K.-U., Tsukamoto Y. et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)// Kidney Int. 2005. Vol. 67. P. 2089–2100.
38. Malluche H.H., Mawad H., Monier-Faugere M.C. The of bone health in end-stage renal disease: out of the frying pan, into the fire // Nephrol Dial Transplant. 2004. Vol. 19. Suppl. 1. P. 9–13.
39. Manns B.J., Hodsman A., Zimmerman D.L. et al. Canadian Society of Nephrology Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD–Mineral and Bone Disorder (CKD-MBD) // Am J Kidney Dis. 2010. Vol. 55. № 5. P. 800–812.
40. Mazzaferro S., Perruzza I., Costantini S. et al. Relative roles of intestinal absorption and dialysis-fluid-related exposure in the accumulation of aluminium in haemodialysis patients // Nephrol. Dial Transplant. 1997. Vol. 12. № 12. P. 2679–2682.
41. Miller J.E., Kovesdy C.P., Norris K.C. et al. Association of Cumulatively Low or High Serum Calcium Levels with Mortality in Long-Term Hemodialysis Patients // Am J Nephrol. 2010. Vol. 32. № 5. P. 403–413.
42. Mittman N., Desiraju B., Meyer K.B. et al. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study // Kidney Int. 2010. Vol. 78. Suppl. 117. P. 33–36.
43. Moe S., Drüeke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO) // Kidney Int. 2006. Vol. 69. № 11. P. 1945–1953.
44. Molina P., Sánchez-Pérez P., Peris A. Two Year Outcomes of a New Treatment Protocol for Controlling Bone Metabolism Parameters in Hemodialysis Patients // ASN Renal week. 2009. Abstract F-PO1854.
45. Monier-Faugere M.C., Malluche H.H. Trends in renalosteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients // Nephrol Dial Transplant. 1996. Vol. 11. Suppl. 3. P. 111–120.
46. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease // Am J Kidney Dis. 2003. Vol. 42. P. 1–201.
47. Navaneethan S.D., Palmer S.C., Craig J.C. et al. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials // Am J Kidney Dis. 2009. Vol. 54. № 4. P. 619–637.
48. Nguyen-Yamamoto L., Bolivar I., Strugnell S.A. et al. Comparison of Active Vitamin D Compounds and a Calcimimetic in Mineral Homeostasis // J Am Soc Nephrol. 2010. Vol. 21. P. 1713–1723.
49. NKF: KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification // Am J Kidney Dis. 2002. Vol. 39. Suppl. 1. P. 1–266.
50. Onoda N., Kurihara S., Sakurai Y. et al. Evaluation of blood supply to the parathyroid glands in secondary hyperparathyroidism compared with histopathology // Nephrol Dial Transplant. 2003. Vol. 18. Suppl. 3. P. 34–37.
51. Pisoni R.L., Wikstrom B., Elder S.J. et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS) // Nephrol Dial Transplant. 2006. Vol. 21. № 12. P. 3495–3505.
52. Qunibi W., Moustafa M., Muenz L.R. et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study // Am J Kidney Dis. 2008. Vol. 51. № 6. P. 952–965.
53. Raggi P., Chertov G., Block G. et al. A randomized control trail to evaluate effect of cinacalcet plus low dose vitamin D on vascular calcification in hemodialysis patients // Poster at Clinical Meeting of the National Kidney Foundation, Orlando, FL, April 13–17, 2010.
54. Recommendations for management of renal osteodystrophy and Clinical Algorithms on renal osteodystrophy // Nephrol Dial Transplant. 2000. Vol. 15. Suppl. 5. P. 2–57.
55. Schumock G.T., Walton S.M., Lee T. Comparative Effectiveness of Paricalcitol versus Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis // Nephron Clin Pract. 2010. Vol. 117. № 2. P. 151–159.
56. Shantouf R.S., Budoff M.J., Ahmadi N. et al. Total and Individual Coronary Artery Calcium Scores as Independent Predictors of Mortality in Hemodialysis Patients // Am J Nephrol. 2010. Vol. 31. № 5. P. 419–425.
57. Tentori F., Albert J.M., Young E.W. et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study // Nephrol Dial Transplant. 2009. Vol. 24. P. 963–972.
58. Tentori F., Blayney M.J., Albert J.M. et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS) // Am J Kidney Dis. 2008. Vol. 52. № 3. P. 519–530.
59. Tominaga Y., Matsuoka S., Sato T. et al. Clinical features and hyperplastic pattern of parathyroid gland in hemodialysis patients with advanced secondary hyperparathyroidism refractory to maxacalcitol treatment and required parathyroidectomy // Ther Apher Dial. 2007. Vol. 11. P. 266–273.
60. Tominaga Y., Katayama A., Sato T. et al. Re-operation is frequently required when parathyroid glands remain after initial parathyroidectomy for advanced secondary hyperparathyroidism in uraemic patients // Nephrol Dial Transplant. 2003. Vol. 18. Suppl. 3. P. 65–70.
61. Uhlig K., Berns J.S., Kestenbaum B. et al. KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD–Mineral and Bone Disorder (CKD-MBD) // Am J Kidney Dis. 2010. Vol. 55. № 5. P. 773–799.
62. Ureña P., Jacobson S.H., Zitt E. et al. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study // Nephrol Dial Transplant. 2009. Vol. 24. № 9. P. 2852–2859.
63. Wetmore J.B., Liu S., Krebill R. et al. Effects of Cinacalcet and Concurrent Low-Dose Vitamin D on FGF23 Levels in ESRD // Clin J Am Soc Nephrol. 2010. Vol. 5. № 1. P. 110–116.
64. Winearls C.G., Glassock R.J. Dissecting and refining the staging of chronic kidney disease // Kidney Int. 2009. Vol. 75. № 10. P. 1009–1014.